Skip to Content


In the US, Mogamulizumab (mogamulizumab systemic) is a member of the drug class miscellaneous antineoplastics and is used to treat Mycosis Fungoides.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Therapeutic Categories

Antineoplastic agent

Monoclonal antibody

Chemical Name

Immunoglobulin G1-kappa, anti-[Homo sapiensCCR4 (chemokine (C-C motif) receptor 4, CC chemokine receptor 4, CCR-4, CKR4, k5-5, CD194)], humanized monoclonal antibody;gamma1 heavy chain (1-449) [humanized VH (Homo sapiensIGHV3-21*01 (83.70%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) - Homo sapiensIGHG1*01 (120-449)], (222-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (Homo sapiensIGKV2-29*02 (81.00%) -IGKJ1*01) [11.3.9] (1'-112') - Homo sapiensIGKC*01 (113'-219')]; (228-228":231-231")-bisdisulfide dimer (WHO )

Foreign Names

  • Mogamulizumabum (Latin)
  • Mogamulizumab (German)
  • Mogamulizumab (French)
  • Mogamulizumab (Spanish)

Generic Names

Brand Name


ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.